Immune Response to Shingles Vaccination
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98104
- University of Washington Virology Research Clinic
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 70 years of age or older.
- History of chickenpox.
Exclusion Criteria
- Previous vaccination with Zostavax or with the chickenpox vaccine.
- History of ever having had shingles.
- Been in close contact with a person who had chickenpox or shingles in the past 5 years.
- VZV seronegative
- Taking systemic suppressive regular doses of drugs with anti-VZV activity such as acyclovir, famciclovir, or valacyclovir. Episodic use is allowed. For Cohort 1: medication cannot be taken 24 hours prior to or 30 days after receiving Zostavax per CDC recommendations.
- HIV seropositive.
- Hepatitis C infection or active Hepatitis B infection.
- History of a life-threatening allergic reaction (anaphylactic/anaphylactoid reaction) to gelatin, neomycin, or any other component of shingles vaccine. Neomycin allergy manifested as contact dermatitis is not an exclusion.
- Has immunosuppression as a result of an underlying illness (e.g. leukemia, lymphoma or other malignant neoplasms) or treatment with immunosuppressive or cytotoxic drugs, or use of anticancer chemotherapy or radiation therapy.
- Has long-term use of oral or parenteral steroids (>7 days), or high-dose inhaled steroids (>800 mcg/day of beclomethasone dipropionate or equivalent) within the preceding 6 months (nasal and topical steroids are allowed).
- Women of child-bearing potential only: pregnant or planning to become pregnant 3 months post vaccination
- Donated blood in the past 8 weeks or planning to donate blood during the study
- Weighs less than 110 lbs
- Has any condition or medical history that would, in the opinion of the site principal investigator place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.
Additional exclusions for optional skin biopsy:
- Has an acute or chronic medical condition that, in the opinion of the investigator, would render biopsies unsafe
- History of coagulopathy or taking medication that may cause bleeding (long term aspirin, heparin, coumadin)
- History of keloid formation or excessive scarring
- History of frequent cellulitis or boils (>3 episodes in past 2 years) requiring antibiotic therapy.
- Allergy to lidocaine, silver nitrate, or mupirocin.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 10 persons over 70 years of age that received Zostavax
10 persons over 70 years of age that received Zostavax (single 0.65-mL dose subcutaneously in the deltoid region of the upper arm)
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Th1 Cytokine Positive VZV-specific CD4 T-cells in Blood
Time Frame: 6 months
|
To determine if Zostavax, when given as FDA indicated, boosts VZV-specific T-cells in the blood
|
6 months
|
|
Percentage of Th1 Cytokine Positive VZV-specific CD4 T-cells in Skin
Time Frame: 4 weeks
|
To determine if shingles disease boosts the local level of VZV-specific T cells in skin 4 weeks after Zostavax
|
4 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Adverse Events Due to Zostavax
Time Frame: 6 months
|
To measure the occurrence of adverse events after Zostavax.
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- STUDY00001399
- 53354 (Other Grant/Funding Number: Merck)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.